SOURCE: Eisai Co., Ltd. and Eisai Inc.

October 08, 2006 21:00 ET

Eisai Receives Summary Judgment Motion Decisions in U.S. Legal Action Over Aciphex® ANDA Filings

TEANECK, NJ -- (MARKET WIRE) -- October 8, 2006 -- Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) and Eisai Inc. (Headquarters: New Jersey, Chairman and CEO: Hajime Shimizu) today announce that they received court decisions on ANDA-related summary judgment motions for Aciphex® (Active Ingredient Name: rabeprazole sodium, Product Name in Japan: Pariet®) on October 6, 2006 (U.S. Eastern time).

The Southern District Court of New York granted Eisai's summary judgment motion confirming the validity of the Aciphex® composition of matter patent in its ruling. The Court reserved ruling on the enforceability arguments until after trial. Eisai looks forward to the trial and will vigorously defend its Aciphex® patent in order to protect the company's interests.

Aciphex® has been shown to have a rapid onset of action and a reliable inhibitory effect on acid secretion related to duodenal ulcers and gastroesophageal reflux disease, which are confirmed in clinical studies. Aciphex® was launched in the U.S. in 1999 and is currently marketed worldwide.

About Aciphex

Aciphex® has a well-established safety profile. The most common side effect possibly related to Aciphex® is headache. Symptom relief does not rule out other serious stomach conditions. Patients on Warfarin (such as Coumadin®) may need to be monitored more closely by their doctor. For more information, visit www.aciphex.com or www.eisai.com.

Contact Information

  • Contacts:

    Corporate Communications Department
    Eisai Co., Ltd.
    TEL: +81-3-3817-5120

    Cathy Pollini
    Corporate Planning and Communications
    Eisai Inc.
    TEL: +1-201-287-2052